Did FIRE-3 study results change in any way your off-protocol practice?
Did FIRE-3 study results change in any way your off-protocol practice?
Will the results of the Phase III FIRE-3 study comparing first-line FOLFIRI/bevacizumab to FOLFIRI/cetuximab in patients with KRAS wt metastatic colorectal cancer (mCRC) in any way change your practice?
Which EGFR Ab preferred 1st as Tx for mCRC? Ever use other EGFR Ab later?
Which EGFR Ab preferred 1st as Tx for mCRC? Ever use other EGFR Ab later?
Which EGFR antibody do you usually use first in the treatment of mCRC?
Do you usually use the other EGFR antibody at a later point in treatment?
Tx 60 yo w/ liver mets, questionable resectablility, 18 mo after adj FOLFOX?
Tx 60 yo w/ liver mets, questionable resectablility, 18 mo after adj FOLFOX?
What treatment approach would you most likely recommend for a 60-year-old patient with KRAS wt colon cancer who presents 18 months after adjuvant FOLFOX with 4 bilateral liver lesions that are questionable in terms of resectability but may be operable if a response is achieved?
1st-line Tx 60 yo w/ unresectable mets 1 y after adj FOLFOX? Pt age at which you don’t want to use bev?
1st-line Tx 60 yo w/ unresectable mets 1 y after adj FOLFOX? Pt age at which you don’t want to use bev?
What is your usual recommendation for first-line therapy for a 60-year-old patient who presents with widespread, unresectable metastases (PS = 0) 12 months after completion of adjuvant FOLFOX for Stage III KRAS wild-type (wt) colon cancer?
The patient had fared well on adjuvant FOLFOX except for minimal peripheral neuropathy that resolved in 6 months.
COCCRC13/1
TARGET AUDIENCE
This activity is intended for medical oncologists, hematologist-oncologists, hematology-oncology fellows, oncology nurses, radiation oncologists, colorectal-general surgeons and other healthcare practitioners involved in the management of colorectal cancer.
OVERVIEW OF ACTIVITY